Skip to content

Author

F. Tacke

We have 11 of 1,497 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jun 2026

New Paradigms in Hepatitis D: Screening, Treatment, and the Path to Cure

Abstract Chronic hepatitis D virus infection, also known as chronic hepatitis delta, remains the most severe form of chronic viral hepatitis, associated with accelerated liver disease progression, cirrhosis, decompensation, and hepatocellular carcinoma. Recent years have seen major advances in screening strategies and...

T. Herta, C. Gaebler, J. Wiegand et al. · 0 citations
Open access Oct 2026

Epithelial NF-κB shapes protective Treg cell responses to restrain intestinal inflammation

Inflammation resolution depends on coordinated communication between tissue compartments, yet how the intestinal epithelium shapes its immune microenvironment remains poorly understood. Here, using colonic biopsies from patients with ulcerative colitis (UC) and mouse models enabling tissue-wide visualization of NF-κB a...

Luisa Barleben, Antony Schneegans, B. Uyar et al. · 0 citations
Review Open access Sep 2026

Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.

Overall, mono- and dual-incretin agonist therapies represent a significant advance in the treatment landscape of MASLD/MASH, although long-term outcome data are required to confirm durability, safety, and impact on major adverse liver-related outcomes.

S. Chirapongsathorn, F. Tacke · 0 citations
Open access Oct 2026

The cell cycle regulator Cyclin E1 drives macrophage-associated inflammatory responses in acute immune-mediated hepatitis

Background and aims Cyclin E1 is a canonical regulator of cell cycle progression known to promote liver fibrosis and hepatocarcinogenesis. However, its precise contribution to hepatic immune responses remains poorly understood. We investigated whether Cyclin E1 regulates macrophage-associated inflammation and acute imm...

C. Penners, Cheng Lin, Alexander Jans et al. · 1 citation
Open access Oct 2026

Microbiota-host genetic interactions modulate MASLD risk in PNPLA3I148M carriers via ceramides and are reversible by targeted microbial interventions.

BACKGROUND The factors that determine when genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) progresses to clinically significant liver injury remain incompletely understood. OBJECTIVE We investigated whether disruption of the intestinal host-microbiota interface acts as a con...

Madhuri Haque, T. Lesker, U. Rolle-Kampczyk et al. · 0 citations
Open access Sep 2026

Comparative Pharmacokinetics of Trientine Dihydrochloride Capsules: A Randomized, Open-Label, Reference-Controlled, Two-Period Crossover Study in Healthy Volunteers.

BACKGROUND AND OBJECTIVES Trientine dihydrochloride (TETA-2HCl) is an oral copper chelator used for Wilson disease. Because available formulations differ in marketed strength and may have formulation-specific pharmacokinetic properties, this study compared a 250 mg test capsule and a 300 mg reference capsule administer...

C. Hartmann, F. Tacke, I. Mohr et al. · 0 citations
Review Open access Sep 2026

Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Emerging therapeutics through a liver cell-centered framework are summarized, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cel...

Han-Yang Liu, Ming-Yuan Zhang, F. Tacke · 0 citations
Review Sep 2026

Molecular mechanisms and pathogenesis of MASH

The state of the art of molecular and cellular mechanisms underlying MASH pathogenesis and its transition to hepatocellular carcinoma are highlighted.

S. Gallage, Olivier Govaere, Q. Anstee et al. · 3 citations
#protein folding Open access Sep 2026

A full-thickness spatial transcriptomics atlas of medically refractory ulcerative colitis identifies niche signatures associated with biologic non-response

Ulcerative colitis (UC) is a chronic mucosal immune disorder in which 30-50% of patients fail biologic therapy, yet the full-thickness immune architecture of medically refractory disease and reliable tissue-level markers of treatment response remain undefined. Using 10x Visium HD spatial transcriptomics (16-...

Qing-Quan Bai, Run-Yang Li, Zheng-Jin Liu et al. · 0 citations
Open access Aug 2026

Mesenchymal R-spondin 3 promotes an immunogenic tumor microenvironment with adaptive immune resistance in human gastric adenocarcinoma.

Positive associations between RSPO3 expression and inflammation suggest that RSPO3 signaling contributes to shaping the immune microenvironment of human intestinal-type GC, a phenotype specific to intestinal-type GC.

Anne-Sophie Fischer, Alexander Arnold, Hilmar Berger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.